Dynamic volume perfusion CT in patients with lung cancer: Baselineperfusion characteristics of different histological subtypes

European Journal of Radiology

Volumn 82, Issue 12, 2013, Pages

  Shi, Jingyun ^a,b   Schmid Bindert, Gerald ^b   Fink, Christian ^c   Sudarski, Sonja ^c   Apfaltrer, Paul ^b   Pilz, Lothar R ^c   Liu, Bo ^d   Haberland, Ulrike ^e   Klotz, Ernst ^e   Zhou, Caicun ^a   Schoenberg, Stefan O ^b   Henzler, Thomas ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Siemens Healthcare ^*  (China)

^e SIEMENS AG   (Germany)

Author keywords

Dynamic volume perfusion CTTumor angiogenesis; Functional imaging; Lung cancer

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD VOLUME; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DYNAMIC VOLUME PERFUSION COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; LUNG BIOPSY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; ONCOLOGICAL PARAMETERS; PERMEABILITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR BLOOD FLOW; TUMOR BLOOD VOLUME; TUMOR MEAN TRANSIT TIME; TUMOR PERMEABILITY; TUMOR VOLUME;

DYNAMIC VOLUME PERFUSION CT; FUNCTIONAL IMAGING; LUNG CANCER; TUMOR ANGIOGENESIS;

AGED; AGED, 80 AND OVER; CHINA; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERFUSION IMAGING; PULMONARY CIRCULATION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 84890787624     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2013.08.023     Document Type: Article

References (33)

1. Chen WQ, Zhang SW, Zou XN, Zhao P. An analysis of lung cancer mortalityin China, 2004-2005. Zhonghua yu fang yi xue za zhi
2. Camps C, Sirera R, Iranzo V, Taron M, Rosell R. Gene expression and poly-morphisms of DNA repair enzymes: cancer susceptibility and response tochemotherapy. Clin Lung Cancer 2007;8(6):369-75.
3. Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation crite-ria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009;45(2):228-47.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate theresponse to treatment in solid tumors, European Organization for Research andTreatment of Cancer, National Cancer Institute of the United States, NationalCancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-16.
5. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobservervariability in measurement of non-small-cell carcinoma lung lesions: implica-tions for assessment of tumor response. J Clin Oncol 2003;21(13):2574-82.
6. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed againstnew targets: if you are fazed, too, then resist RECIST. J Clin Oncol2004;22(22):4442-5.
7. Drevs J, Schneider V. The use of vascular biomarkers and imaging studies inthe early clinical development of anti-tumour agents targeting angiogenesis. JIntern Med 2006;260(6):517-29.
8. Li Y, Yang ZG, Chen TW, Deng YP, Yu JQ, Li ZL. Whole tumour perfusion ofperipheral lung carcinoma: evaluation with first-pass CT perfusion imaging at64-detector row CT. Clin Radiol 2008;63(6):629-35.
9. Swensen SJ. Functional CT: lung nodule evaluation. Radiographics2000; 20(4):1178-81.
10. Swensen SJ, Brown LR, Colby TV, Weaver AL. Pulmonary nodules: CTevaluation of enhancement with iodinated contrast material. Radiology1995;194(2):393-8.
11. Swensen SJ, Morin RL, Schueler BA, et al. Solitary pulmonary nodule: CT evalu-Ation of enhancement with iodinated contrast material-A preliminary report.Radiology 1992;182(2):343-7.
12. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT:multicenter study. Radiology 2000;214(1):73-80.
13. Yamashita K, Matsunobe S, Tsuda T, et al. Solitary pulmonary nodule:preliminary study of evaluation with incremental dynamic CT. Radiology1995;194(2):399-405.
14. Zhang M, Kono M. Solitary pulmonary nodules: evaluation of blood flow pat-terns with dynamic CT. Radiology 1997;205(2):471-8.
15. Ohno Y, Koyama H, Matsumoto K, et al. Differentiation of malignant and benignpulmonary nodules with quantitative first-pass 320-detector row perfusion CTversus FDG PET/CT. Radiology 2011;258(2):599-609.
16. Fraioli F, Anzidei M, Zaccagna F, et al. Whole-tumor perfusion CT in patientswith advanced lung adenocarcinoma treated with conventional and antiangio-genetic chemotherapy: initial experience. Radiology 2011;259(2):574-82.
17. Tacelli N, Remy-Jardin M, Copin MC, et al. Assessment of non-small celllung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology2010;257(3):863-71.
18. Sauter AW, Winterstein S, Spira D, et al. Multifunctional profiling of non-smallcell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med2012;53(4):521-9.
19. Spira D, Neumeister H, Spira SM, et al. Assessment of tumor vascularity in lungcancer using volume perfusion CT (VPCT) with histopathologic comparison: afurther step toward an individualized tumor characterization. J Comput AssistTomogr 2013;37(1):15-21.
20. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new WorldHealth Organization classification of lung tumours. Eur Respir J 2001;18(6):1059-68.
21. European Guidelines on Quality Criteria for Computed Tomography. ReportEUR 16262. Brussels, Belgium: European Commission; 1999.
22. Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N.Contrast-enhanced dynamic computed tomography for the evaluation of tumorangiogenesis in patients with lung carcinoma. Cancer 2002;95(4):835-42.
23. Travis WD. Update on small cell carcinoma and its differentiation fromsquamous cell carcinoma and other non-small cell carcinomas. Mod Pathol2012;25(Suppl. 1):S18-30.
24. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advancednon-small cell lung cancer: perfusion CT evaluation of chemotherapy and radi-Ation therapy. AJR Am J Roentgenol 2009;193(4):1090-6.
25. Li SP, Makris A, Gogbashian A, Simcock IC, Stirling JJ, Goh V. Predictingresponse to neoadjuvant chemotherapy in primary breast cancer using volu-metric helical perfusion computed tomography: a preliminary study. Eur Radiol2012;22(9):1871-80.
26. Mileshkin L, Hicks RJ, Hughes BG, et al. Changes in 18F- fluorodeoxyglucoseand 18F-fluorodeoxythymidine positron emission tomography imaging inpatients with non-small cell lung cancer treated with erlotinib. Clin CancerRes 2011;17(10):3304-15.
27. Benz MR, Herrmann K, Walter F, et al. (18)F-FDG PET/CT for monitoring treat-ment responses to the epidermal growth factor receptor inhibitor erlotinib. JNucl Med 2011;52(11):1684-9.
28. Zander T, Scheffler M, Nogova L, et al. Early prediction of nonprogres-sion in advanced non-small-cell lung cancer treated with erlotinib byusing [(18)F]fluorothymidine positron emis-sion tomography. J Clin Oncol 2011;29(13):1701-8.
29. Schmid-Bindert G, Henzler T, Chu TQ, et al. Functional imaging of lung can-cer using dual energy CT: how does iodine related attenuation correlate withstandardized uptake value of 18FDG-PET-CT? Eur Radiol 2012;22(1):93-103.
30. Yumuk PF, Mohammed N, Maat AP, Fink C, Marchal B, O'Brien ME. Howdo lung cancer specialists follow their patients with stage III non-small celllung cancer (NSCLC) after definitive treatment? - a short report. Eur J Cancer2012;48(14):2163-5.
31. Goh V, Dattani M, Farwell J, et al. Radiation dose from volumetric helical per-fusion CT of the thorax, abdomen or pelvis. Eur Radiol 2011;21(5):974-81.
32. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment withmultidetector CT: are measurements from two commercial software packagesinterchangeable? Radiology 2007;242(3):777-82.
33. Ng QS, Goh V, Fichte H, et al. Lung cancer perfusion at multi-detector rowCT: reproducibility of whole tumor quantitative measurements. Radiology2006;239(2):547-53